Melane Sampson, Author at BioTuesdays

Developments

FDA grants accelerated approval of Rocket’s KRESLADI for pediatric LAD-I

Rocket Pharmaceuticals (NASDAQ: RCKT) has announced FDA approval of KRESLADI, an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients with severe leukocyte adhesion...

March 27, 2026

Developments

FDA clears Lantern/Starlight’s IND for trial of STAR-001 in pediatric cancer

Lantern Pharma (NASDAQ: LTRN) and its subsidiary, closely held Starlight Therapeutics, have announced FDA clearance of the investigational new drug (IND) application for STAR-001, in a planned Phase 1 pediatric clinical...

March 27, 2026

Developments

Profound congratulates Texas Prostate’s 100th TULSA Procedure milestone

Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure performed in Dallas Medical Center’s state-of-the-art MRI suite. “Having...

March 27, 2026

Developments

NextPlat expands reach through collaboration with HealthWarehouse.com

NextPlat (NASDAQ: NXPL; NXPLW) has announced a collaboration with HealthWarehouse.com (OTCQB: HEWA) to enable nationwide fulfillment of prescription and over-the-counter (OTC) products. According to NextPlat, the...

March 26, 2026

Executive Moves

Wang Haijiao joins Fangzhou as CEO

Fangzhou (HKEX: 06086) has announced the appointment of Wang Haijiao as chief executive officer (CEO) and executive director, effective today. Mr. Wang’s nearly 20 years of extensive healthcare industry experience in...

March 26, 2026

Developments

Firefly confirms public-private partnership with DoW

Firefly Neuroscience (NASDAQ: AIFF) has announced a partnership with the Department of War (DoW) to support the assessment and treatment of active-duty U.S. service members and veterans suffering from post-traumatic...

March 26, 2026

Uncategorized

IceCure reports positive 5-year results from ProSense kidney cancer study

IceCure Medical (NASDAQ: ICCM) has announced positive topline results from the ICESECRET clinical study of its ProSense Cryoablation System for the treatment of small renal masses in kidney cancer patients. Detailed...

March 25, 2026

Developments

Amplia reports more responses and improved OS in pancreatic cancer trial

Amplia Therapeutics (ASX: ATX; OTCQB: INNMF) has announced data from the ongoing ACCENT clinical trial of narmafotinib combined with chemotherapy in advanced pancreatic cancer showing a median overall survival (OS) of...

March 23, 2026

Developments

Bioxytran completes $1.2 million private placement

Bioxytran (OTC: BIXT) has announced that it has completed a private placement financing on March 18, 2026, resulting in gross proceeds of approximately $1.2 million. In connection with the financing, the company issued...

March 20, 2026

Developments

Co-Diagnostics inks agreement to expand distribution across South Asia

Co-Diagnostics (NASDAQ: CODX) has signed an agreement for closely held CoSara Diagnostics—the Indian joint venture between Co-Dx and Ambalal Sarabhai—to significantly expand its commercial and distribution territory...

March 20, 2026

Author - Melane Sampson

FDA grants accelerated approval of Rocket’s KRESLADI for pediatric LAD-I

FDA clears Lantern/Starlight’s IND for trial of STAR-001 in pediatric cancer

Profound congratulates Texas Prostate’s 100th TULSA Procedure milestone

NextPlat expands reach through collaboration with HealthWarehouse.com

Wang Haijiao joins Fangzhou as CEO

Firefly confirms public-private partnership with DoW

IceCure reports positive 5-year results from ProSense kidney cancer study

Amplia reports more responses and improved OS in pancreatic cancer trial

Bioxytran completes $1.2 million private placement

Co-Diagnostics inks agreement to expand distribution across South Asia

Subscribe